Discussion
cancer
ASYMPTOMATIC SARS-COV-2 INFECTION, CANCER
Since the authorization of third doses for patients with a weakened immune system, several studies have shown enhanced immunogenicity for a third dose of COVID-19 vaccine in patients with cancer (Correlation between anti-S antibody titers and neutralization activity in patients with cancer has been demonstrated (Our results demonstrate that a third dose of COVID-19 vaccine boosts detectable anti-S immunity in the majority of cancer patients and can seroconvert a subset of them not responding to primary two-vaccine doses. The third COVID-19 vaccine also results in boosting of T-cell responses and leads to a rise in neutralizing antibodies. Patients who have received anti-CD20 antibody therapy or BTK inhibitors remain at risk for lower seroconversion whereas those who have been infected with COVID-19 in the past have a very strong immune response likely due to immunologic memory. Our results show that the higher the titer of the anti-S antibody, the higher likelihood of neutralization in a surrogate neutralization assay adding to the evidence that this may be a good strategy to prevent symptomatic SARS-CoV-2 infection as well as an appropriate surrogate marker to guide research and clinical management (Reports of efficacy of fourth COVID-19 vaccine doses are emerging. A study from Israel demonstrated enhanced Omicron neutralization after a fourth dose of COVID-19 mRNA vaccine in healthy healthcare workers (